CVRx opens THT2026 with new scientific data on Barostim outcomes

CVRx opens THT2026 with new scientific data on Barostim outcomes
CVRx unveils Barostim data

CVRx launches THT2026 today, featuring a comprehensive program of scientific presentations focused on Barostim.

Attendees will gain insight from late-breaking clinical data, oral sessions, and research posters that emphasize real-world outcomes, advances in cardiac energetics, and broader impacts of Barostim therapy. The event is positioned as a central forum for researchers and clinicians to examine the latest evidence in device-based modulation of cardiovascular function.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.